Nano-X Imaging Ltd. (NASDAQ: NNOX) is advancing its medical imaging analytics subsidiary, Nanox.AI, on two fronts: a new commercial partnership in the United Kingdom and a technical collaboration with Intel. The moves aim to address a persistent gap in diagnostic imaging, where scans ordered for one clinical question often contain additional anatomical information that goes unexamined.
On the commercial side, Nanox.AI has signed an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution. The deal includes minimum annual license commitments, providing a predictable revenue stream. HealthOST is designed to help clinicians assess bone health from routine CT scans, potentially identifying vertebral fragility fractures that might otherwise be missed. According to data referenced in the announcement, approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed. By partnering with Vertec Scientific, Nanox.AI gains a direct channel to UK hospitals and imaging centers, where early detection could improve patient outcomes and reduce downstream costs.
In parallel, Nanox.AI is working with Intel on an optimization project that demonstrates a path for its imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud. This is significant because local processing can reduce latency, address data privacy concerns, and lower bandwidth requirements. For hospitals, it means AI insights could be delivered faster and more reliably, without depending on external network connections. The project also highlights the scalability of Nanox.AI's technology, as it can be deployed across different hardware configurations.
Both initiatives support Nanox.AI's broader strategy of extracting more value from existing medical scans. A CT scan ordered to answer one clinical question may capture information related to the spine, coronary arteries, liver, and other areas. Nanox.AI's algorithms analyze these images to surface findings that may otherwise go unnoticed, supporting clinical evaluation without additional imaging procedures. This approach could lead to earlier interventions and more comprehensive patient care.
For investors, the announcements signal progress in commercializing Nanox.AI's technology. The exclusive UK agreement with minimum commitments provides near-term revenue visibility, while the Intel collaboration positions the company for broader adoption in cost-sensitive healthcare environments. The news was originally distributed via NEWMEDIAWIRE, and further details are available in the company's newsroom at https://ibn.fm/NNOX. Full terms of use and disclaimers are available at https://IBN.ai/Disclaimer. The original release can be viewed at www.newmediawire.com.
As healthcare systems seek to do more with existing resources, technologies that unlock hidden data from routine scans could become increasingly valuable. Nanox.AI's dual approach—expanding commercial reach while optimizing deployment—may position it to capture a growing share of the medical imaging AI market.
